Safety and Efficacy of Honeycomb Microporous Covered Stents (NCVC-CS1) for the Treatment of Intracranial Aneurysms (NCVC-CS1_UAN)

Safety and Efficacy of Honeycomb Microporous Covered Stents (NCVC-CS1) for the Treatment of Intracranial Aneurysms: a Multicenter, Uncontrolled, Exploratory Trial

This trial is conducted to evaluate the safety and technical effectiveness of using NCVC-CS1, a newly developed honeycomb microporous covered stent, for the treatment of intracranial aneurysms which are difficult to be cured by conventional surgical or endovascular procedures.

Study Overview

• Status: Completed
• Conditions: Intracranial Aneurysm
• Intervention / Treatment: Device: NCVC-CS1

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Japan
  • Kyoto, Japan, 6068507
    • Kyoto University Hospital
  • Hyogo
    • Kobe, Hyogo, Japan, 650-0047
      • Kobe City General Hospital
  • Osaka
    • Suita, Osaka, Japan, 565-8565
      • National Cerebral and Cardiovascular Center
  • Tokyo
    • Bunkyo-ku, Tokyo, Japan, 113-8431
      • Juntendo University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 75 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

(Provisional registration)

1. Age between 20 and 75 years.

2. Target lesion is an unruptured aneurysm regardless of prior treatment diagnosed by angiography, CTA, or MRA within 180 days

   • Target aneurysm located in petrous/cavernous portion of internal carotid artery, intradural vertebral artery except for its union, or basilar artery below the orifice of superior cerebellar artery.
   • Target aneurysm is considered difficult to treat by conventional surgical/endovascular procedures
   • Target aneurysm with a sac diameter exceeding 7 mm.
   • Target aneurysm with a neck diameter over 4 mm or with a ratio "dome/neck" smaller than 2.
3. Modified Rankin score of 3 or less
4. Agreement for participating in the study and informed consent signed by the patient.

(definitive registration)

1. Target lesion must be reconfirmed by angiography or interventional procedure and is compatible with the conditions as follows:

• Target aneurysm located in petrous/cavernous portion of internal carotid artery, intradural vertebral artery except for its union, or basilar artery below the orifice of superior cerebellar artery.
• Target aneurysm is considered difficult to treat by conventional surgical/endovascular procedures
• Target aneurysm with a sac diameter exceeding 7 mm.
• Target aneurysm with a neck diameter over 4 mm or with a ratio "dome/neck" smaller than 2.
• Parent artery of target aneurysm is accessible by the investigational devices
• The diameter of the parent artery between 3.5 and 5 mm.

Exclusion Criteria:

(Provisional registration)

1. Any invasive surgical procedure within 30 days before registration.
2. Prior stent implantation at the site of target aneurysm
3. Existence of intracranial tumor, arteriovenous malformation for which any intervention is considered necessary, or co-existence of unruptured intracranial aneurysm whose sac diameter over 5mm within the target vessel.
4. Coexistence of other unruptured intracranial aneurysms which are planned for intervention
5. Target vessel not suitable for delivery and placement of covered stent because of anatomical configuration (i.e. severe bend or tortuosity).
6. More than 50% stenosis in the target vessel or its proximity including extracranial region.
7. Any intracranial hemorrhage within 42 days before registration.
8. Co-morbid conditions that may limit survival to less than 6 months, or difficult to observe the patient for 6 months.
9. Renal dysfunction whose serum creatinine more than 2.0
10. Contraindications to antiplatelet or anticoagulant treatment because of allergy or hemorrhagic diathesis.
11. Platelets less than 100,000/mm3 or known dysfunction of platelets.
12. Active bacterial infection.
13. Any cardiac, hematological, intracranial, or vessel disease which are considered to have high risk of neurological events (severe cardiac failure, atrial fibrillation, arteritis, known carotid artery stenosis, etc.).
14. History of severe allergy to contrast dye.
15. Known allergy to cobalt-chromium alloy and polyurethane. clopidogrel, heparin, nitinol, local or general anesthesia
16. Subjects who have enrolled, or are planned to participate in other clinical trial or intervention study.
17. Pregnant woman
18. Unsuitable patients judged by the physician attending this trial.

(definitive registration)

1. History of any invasive surgical procedure after the provisional registration.
2. Any new neurological signs within 24 hours prior to the procedure.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Treatment group; neuroendovascular therapy(NCVC-CS1)	Device: NCVC-CS1; Intervention Description

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Safety evaluation: Any stroke or death related to the procedure within 180 days	180 days after the procedure
Efficacy evaluation: Complete obliteration of target aneurysm and patency of target vessel (less than 50% stenosis) confirmed by angiography at 180 days after the procedure	180 days after the procedure

Secondary Outcome Measures

Outcome Measure	Time Frame
Technical success (stent placement in the target lesion covering aneurysmal neck without occlusion of target vessel)	180 days after the procedure
Any death within 180 days after the procedure	180 days after the procedure
Any death by neurological reason within 180 days after the procedure	180 days after the procedure
Any adverse event or adverse device effect	180 days after the procedure
Neurological assessment (scale ; mRS)	180 days after the procedure
Neurological assessment (scale ; Barthel Index)	180 days after the procedure
Neurological assessment (scale ; NIHSS)	30 days after the procedure
Neurological assessment (scale ; GCS)	30 days after the procedure

Collaborators and Investigators

• Sponsor: National Cerebral and Cardiovascular Center
• Collaborators: Juntendo University; Kyoto University; Kobe City General Hospital
• Investigators: Principal Investigator: Tetsu Satow, National Cerebral and Cardiovascular Center

Publications and helpful links

General Publications

• Yamamoto H, Hamasaki T, Onda K, Nakayama Y, Ishii A, Oishi H, Sakai N, Satow T. Evaluating the safety and technical effectiveness of a newly developed intravascular 'flow isolator' stent for the treatment of intracranial aneurysms: study protocol for a first-in-human single-arm multiple-site clinical trial in Japan. BMJ Open. 2019 May 9;9(5):e020966. doi: 10.1136/bmjopen-2017-020966.

Study record dates

Study Major Dates

• Study Start (ACTUAL): May 1, 2016
• Primary Completion (ACTUAL): January 25, 2019
• Study Completion (ACTUAL): March 4, 2019

Study Registration Dates

• First Submitted: September 1, 2016
• First Submitted That Met QC Criteria: September 15, 2016
• First Posted (ESTIMATE): September 20, 2016

Study Record Updates

• Last Update Posted (ACTUAL): March 13, 2019
• Last Update Submitted That Met QC Criteria: March 11, 2019
• Last Verified: March 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Intracranial Arterial Diseases; Aneurysm; Intracranial Aneurysm
• Other Study ID Numbers: NCVC-CS1_UAN

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO